| Dec 07 | Dec 06 | Dec 05 | Dec 04 | Dec 03 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | |||||
| Gross Profit | $ 3.10K | $ 145.28K | $ 427.36K | $ 257.89K | $ 149.69K |
| Operating Income | $ -4.91M | $ -4.81M | $ -2.84M | $ -7.60M | $ -2.70M |
| EBITDA | $ -4.45M | $ -4.27M | $ -2.08M | $ -6.88M | $ -2.52M |
| Net Income | $ -6.58M | $ -4.97M | $ -3.69M | $ -7.87M | $ -3.70M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― | $ ― | $ ― |
| Total Assets | $ 7.22M | $ 7.82M | $ 8.97M | $ 9.68M | $ 6.04M |
| Total Debt | $ 4.12M | $ 5.37M | $ 2.49M | $ 256.45K | $ 5.73M |
| Net Debt | $ 4.12M | $ 5.33M | $ 2.48M | $ 238.54K | $ 5.68M |
| Total Liabilities | $ 9.58M | $ 9.14M | $ 6.51M | $ 3.57M | $ 6.85M |
| Stockholders' Equity | $ ― | $ ― | $ ― | $ ― | $ ― |
| Cash Flow | |||||
| Free Cash Flow | $ -912.42K | $ -2.60M | $ -2.41M | $ -3.43M | $ -2.17M |
| Operating Cash Flow | $ -910.89K | $ -2.58M | $ -2.37M | $ -3.40M | $ -2.16M |
| Investing Cash Flow | |||||
| Financing Cash Flow |
Nanobac Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.